

PAZOPANIB FACT SHEET

What is pazopanib?

- Pazopanib is an oral, investigational angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-kit, key proteins responsible for tumor growth and survival.¹
- Pazopanib is an investigational drug and is not yet approved by any regulatory agency.

How does pazopanib work?

- Pazopanib is orally administered and has shown activity in inhibiting angiogenesis, the process that supports the development of tumor growth and progression.¹ Pazopanib targets VEGFR, PDGFR, and c-kit, which are believed to not only promote angiogenesis but tumor growth.¹

What data support pazopanib?

- Activity was detected against several tumor types in pre-clinical studies with pazopanib, including prostate, colon, lung, melanoma, breast and renal cancer.¹ These results led to the initiation of further investigations across a range of malignances.¹
- A global, Phase II study demonstrated the activity of pazopanib in patients with RCC who have not received prior systemic therapy or have failed one prior therapy (cytokine or bevacizumab-containing regimen).²
- Pazopanib is being investigated in a broad development program; clinical trials are currently underway in advanced breast cancer, recurrent ovarian cancer, soft tissue sarcoma, non-small cell lung cancer (NSCLC) and other solid tumors.¹ It is being evaluated as a monotherapy and in combination with other oral targeted agents and chemotherapy.
- Pazopanib has also been studied in renal cell carcinoma (RCC) and an additional study in this disease setting is planned for later this year.

In what areas is pazopanib being studied?

- Pazopanib is being investigated in a broad development program; clinical trials are currently underway in RCC, advanced breast cancer, recurrent ovarian cancer, soft tissue sarcoma, non-small cell lung cancer (NSCLC) and other solid tumors.¹ It is being evaluated as a monotherapy and in combination with other oral targeted agents and chemotherapy.

References

¹ Sonpavde, G. and Hutson, T. Pazopanib: A Novel Multitargeted Tyrosine Kinase Inhibitor. *Curr Oncol Rep.* 2007; Mar;9(2):115-9

²Hutson, T.E., *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 5031